The latest EU Pharma Figures clearly show Belgium has a leading position within the European Union in terms of biopharmaceutical research and development, production and export, says the sector’s trade group pharma.be in a website posting.
Although Belgium has only 2.6% of the EU population, the biopharma industry accounts for 7.8% of jobs, 18.7% of exports and 19.3% of R&D investments in the EU. This puts the sector in third, second and first place in Europe respectively.
Because of this top position, it is important that the country asserts itself at European level in important dossiers at hand, such as the revision of European pharmaceutical regulations and intellectual property rights. Especially when Belgium is President of the European Council in the first half of next year, the pharma.be stressed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze